TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Trending·November 2, 2026

Tempus AI, Inc. (TEM) climbs 12% on Q3 beat

Tempus AI, Inc. (TEM) climbs after posting a strong Q3 revenue beat, swinging to adjusted EPS profit, and lifting 2026 revenue guidance. The rally reflects improved operating leverage, stronger growth across its core businesses, and renewed investor confidence in the company’s outlook.

TrendingTEM
By TickerSpark·November 2, 2026·5 min read
Tempus AI, Inc. (TEM) climbs 12% on Q3 beat
▌Key Takeaway
Tempus AI, Inc. (TEM) climbed 12.03% after reporting a strong Q3 earnings beat, including $411.5 million in revenue and adjusted EPS of $0.07 versus expectations for a loss. The company also raised its 2026 revenue outlook, signaling improving execution and stronger confidence in its growth trajectory. For investors, the move reinforces the bullish case, but valuation and volatility remain key risks after the sharp rally.

Tempus AI, Inc. (TEM) climbs 12.03% to $80.91 at the 3 p.m. ET print on Nov. 2, 2026, while relative volume reaches 1.9x its 200-day average. The move follows a clear catalyst: Q3 revenue of $411.5M, an adjusted EPS beat, and a raised 2026 revenue outlook.

Key Takeaways

  • TEM climbed 12.03% to $80.91, with 1.9x relative volume and 12.72 million shares traded intraday.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Q3 revenue reached $411.5M, up 23% year over year, while adjusted EPS came in at $0.07 versus a $0.09 loss estimate.
  • Tempus raised 2026 revenue guidance to $1.60B to $1.605B from $1.59B and kept adjusted EBITDA guidance near $65M.
  • The business showed stronger operating leverage, with adjusted EBITDA rising to $25.6M and net loss narrowing to $14.9M.
  • The earnings reaction is positive, but a $14.34B market cap, -$1.44 EPS, and 3.54 beta keep valuation and volatility firmly in focus.
  • Why Tempus AI (TEM) Climbs Today: Q3 Earnings Beat and Guidance Raise

    Tempus reported its third-quarter 2026 results before the open on Nov. 2. The company delivered $411.54M in revenue for the quarter ended September 2026, up 23.1% year over year. That figure topped the $411.34M consensus estimate by 0.05%.

    The adjusted EPS result carried more weight. Tempus posted adjusted EPS of $0.07, compared with a consensus estimate for a $0.09 loss. The 177.78% earnings surprise gave traders a sharper profitability signal than revenue alone.

    The company also raised full-year revenue guidance from $1.59B to a range of $1.60B to $1.605B. It kept adjusted EBITDA guidance near $65M. That combination supports the most likely catalyst for today's move: stronger execution paired with greater confidence in the full-year outlook.

    Trading activity confirms a broad repricing rather than a thinly traded spike. Intraday volume reached 12.72 million shares, while relative volume stood at 1.9x the 200-day average. Needham also maintained a Buy rating and set an $89 price target on Nov. 2, reinforcing the positive tone after the results.

    Tempus AI Financial Results Show Growth With Smaller Losses

    Tempus delivered improvement across several operating measures. Gross profit rose to $266.7M, and gross margin expanded to 66% from 64% a year earlier. Oncology volume increased 32%, while Data & Applications revenue grew 33%.

    Profitability also moved in the right direction. Adjusted EBITDA reached $25.6M, compared with $1.5M in the prior-year quarter. Net loss narrowed to $14.9M from $80.0M. Tempus still reported a GAAP loss of $0.08 per share, so the improvement does not erase the need for continued execution.

    The guidance update gives investors a concrete forward benchmark. Tempus now expects roughly 25% annual revenue growth in 2026, while retaining its approximately $65M adjusted EBITDA target. The revenue increase is modest in absolute terms, but it confirms that management sees demand holding after a record quarter.

    TEM Valuation, Data Moat, and Competitive Position

    At the $80.91 print, Tempus carries a $14.34B market capitalization. The trailing EPS figure is -$1.44, which makes standard P/E analysis a poor fit. The more relevant valuation debate centers on whether 23% revenue growth and improving EBITDA justify the premium investors assign to the platform.

    Tempus combines diagnostics, analytics, clinical applications, and a multimodal data repository. Its platform connects clinician workflows with laboratory testing and software tools. That structure gives the business two connected engines: diagnostics create data, while data applications expand the commercial value of the platform.

    The company also has relationships with Bristol Myers Squibb (BMY), Moderna (MRNA), Merck (MRK), and Recursion (RXRX). These collaborations add commercial reach across biopharma and support the data licensing narrative. Still, the stock remains a growth investment rather than a low-risk value play. Its 3.54 beta signals the potential for large price swings, while its 52-week range runs from $40.77 to $89.09.

    What the TEM Rally Means for Investors After Earnings

    The analyst backdrop is constructive but not without valuation tension. The consensus rating is Buy, with nine Buy ratings, five Holds, and zero Sell ratings. However, the consensus price target is $74.27, with a $75 median, $50 low, and $92 high. The $74.27 consensus sits below the $80.91 print, showing that strong sentiment does not guarantee immediate upside.

    The cleanest scorecard is already defined by the quarter. Investors assessing TEM can compare future results with 23% revenue growth, 66% gross margin, 32% oncology volume growth, 33% Data & Applications growth, and $25.6M adjusted EBITDA. If those metrics hold, the growth thesis gains support. If growth or margin progress slips, the premium valuation faces more pressure.

    Position sizing also matters. A 12% single-day move and a 3.54 beta create meaningful volatility even when the operating news is favorable. A disciplined approach separates the business case from the trading impulse, especially after a sharp earnings repricing.

    Bottom Line for Tempus AI (TEM) After the Earnings Move

    Tempus AI's 12.03% climb has a specific foundation: a strong Q3, a major adjusted EPS beat, narrower losses, and higher 2026 revenue guidance. The next phase of the investment case rests on whether Tempus can sustain its growth and profitability gains while supporting a $14.34B valuation.

    Read the full TEM research report
    ▌Common Questions

    Frequently asked questions

    +Why is TEM stock up today?
    TEM is up because Tempus AI reported stronger-than-expected Q3 results, including a revenue beat and adjusted EPS of $0.07 versus an expected loss. The company also raised its 2026 revenue guidance, which boosted investor confidence.
    +Should I buy TEM stock now?
    The earnings report is constructive, but TEM already trades at a premium and remains highly volatile. Investors should weigh the improved growth outlook against valuation risk before buying.
    +Did Tempus AI beat earnings estimates?
    Yes. Tempus AI beat both revenue and adjusted EPS expectations in Q3. Revenue came in at $411.5 million, and adjusted EPS was $0.07 versus a consensus estimate for a $0.09 loss.
    +What does the higher 2026 guidance mean for TEM investors?
    The higher 2026 revenue guidance suggests management sees continued demand and better execution ahead. That supports the growth thesis, but investors still need to watch whether Tempus can keep improving margins and profitability.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on TEM?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the TEM report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full TEM research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the TEM report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on TEM

    More to read

    All articles
    Tempus AI (TEM): Growth Momentum vs. Profitability Risk
    TEM

    Tempus AI (TEM): Growth Momentum vs. Profitability Risk

    Tempus AI is scaling quickly in diagnostics and data licensing, with improving margins and a growing multimodal data asset. But losses, negative free cash flow, and leverage keep the stock in Hold territory.

    Nov 20·19 min
    Tempus AI, Inc. (TEM) rises 7% on AI momentum
    TEM

    Tempus AI, Inc. (TEM) rises 7% on AI momentum

    Tempus AI, Inc. (TEM) rises after a new Recursion Pharmaceuticals partnership extension and RNA model agreement fueled renewed interest in its healthcare AI platform. Strong volume, recent FDA clearance, and ARPA-H funding added to the rally, though the stock now trades above several analyst targets.

    Sep 24·5 min